Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 8/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10569550 | 0.86 | SORD (0.54) | SORD | |
| SCHEMBL10564194 | 0.85 | SORD (0.53) | SORD | |
| SCHEMBL14553999 | 0.83 | SORD (0.54) | SORDPIK3CACYP2C19PIK3CDALDH1A1 | |
| SCHEMBL6293482 | 0.82 | HRH3 (0.55) | SORDALDH1A1USP2CYP1A2HSD17B10 | |
| SCHEMBL14554006 | 0.81 | SORD (0.51) | SORDPIK3CACYP2C19PIK3CDALDH1A1 | |
| SCHEMBL27693708 | 0.80 | SORD (0.54) | SORDPIK3CACYP2C19PIK3CDALDH1A1 | |
| SCHEMBL4724828 | 0.80 | SORD (0.78) | SORD | |
| SCHEMBL14552443 | 0.79 | SORD (0.50) | SORDPIK3CACYP2C19PIK3CDALDH1A1 | |
| SCHEMBL14552678 | 0.79 | SORD (0.50) | SORDPIK3CACYP2C19PIK3CDALDH1A1 | |
| Hydrochloric Acid SCHEMBL10332545 | 0.79 | SORD (0.53) | SORDPIK3CACYP2C19PIK3CDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023006097-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | 海创药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| EP-1934228-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007027855-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| US-4956366-A | GASTROINTESTINAL DISORDERS, ANTISECRETORY AGENTS FOR GASTRIC ACID SECRETION | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-09-11 | — | — | US | disclosed |
| US-4820708-A | ANTISECRETORY AGENTS; GASTROINTESTINAL DISORDERS | SMITH KLINE & FRENCH LABORATORIES (GB) | 1989-04-11 | — | — | US | disclosed |
| EP-0299389-A2 | Substituted thieno-imidazole derivatives, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors, gastric protecting agents and as medicaments against intestinal inflammation | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-18 | — | — | EP | disclosed |
| US-4777172-A | ANTIGASTRIC ACID SECRETORY AGENT | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-10-11 | — | — | US | disclosed |
| CN-86102398-A | The preparation method of substituted benzimidazole derivative | — | 1986-11-12 | — | — | CN | disclosed |
| EP-0198583-A1 | Heterocyclic compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | SORD 408/4885PIK3CA 234/4885CYP2C19 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.